La Jolla Pharmaceutical Company
LJPC
LJPC was delisted on the 19th of August, 2022.
96 hedge funds and large institutions have $672M invested in La Jolla Pharmaceutical Company in 2017 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 24 increasing their positions, 17 reducing their positions, and 7 closing their positions.
557% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 7
141% more capital invested
Capital invested by funds: $279M → $672M (+$393M)
55% more funds holding
Funds holding: 62 → 96 (+34)
41% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 17
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
0% more call options, than puts
Call options by funds: $8.45M | Put options by funds: $8.43M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$38.6M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$36.3M |
| 3 |
BlackRock
New York
|
+$23.3M |
| 4 |
PA
Perceptive Advisors
New York
|
+$20.9M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$15.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$18.6M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$6.11M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$5.39M |
| 4 |
Allianz Asset Management
Munich,
Germany
|
-$3.77M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$3.34M |
LJPC Hedge Fund Activity: Q1 2017 in Review
96 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q1 2017, worth a combined $672M — up 141% from $279M a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new LJPC positions and 7 closed out — a net gain of 39 holders — while 24 added to existing stakes and 17 trimmed.
The largest buyer was Jennison Associates, adding an estimated $38.6M. The largest seller was Broadfin Capital, cutting an estimated $18.6M.
- 96 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q1 2017, up from 62 in Q4 2016.
- Funds reported $672M of La Jolla Pharmaceutical Company stock for Q1 2017, up 141% quarter-over-quarter.
- 46 funds opened new La Jolla Pharmaceutical Company positions in Q1 2017 and 7 closed out, a net change of +39 holders.
- The largest La Jolla Pharmaceutical Company buyer in Q1 2017 was Jennison Associates, an estimated $38.6M added.
- The largest La Jolla Pharmaceutical Company seller in Q1 2017 was Broadfin Capital, an estimated $18.6M sold.
Based on aggregated 13F filings for Q1 2017.